--- title: "U.S. stock market midday update: Cibus down 11.54%, acquisition boosts financial metrics, but the market remains concerned about future profitability" type: "News" locale: "en" url: "https://longbridge.com/en/news/292937687.md" description: "Cibus fell 11.54%; AbbVie rose 3.40%, with a transaction volume of USD 655 million; Gilead Sciences rose 2.45%, with a transaction volume of USD 375 million; Amgen rose 3.08%, with a transaction volume of USD 287 million; Vertex Pharmaceuticals rose 1.86%, with a market value of USD 123.3 billion" datetime: "2026-07-16T17:57:51.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/292937687.md) - [en](https://longbridge.com/en/news/292937687.md) - [zh-HK](https://longbridge.com/zh-HK/news/292937687.md) --- # U.S. stock market midday update: Cibus down 11.54%, acquisition boosts financial metrics, but the market remains concerned about future profitability **U.S. Stock Market Midday Update** Cibus fell 11.54%. Based on recent news, 1. On July 16, Cibus's earnings per share and net operating income increased due to acquisitions, with occupancy rates rising to 96.1%. Despite fluctuations in the interest rate environment, financial metrics remained stable, but market concerns about its future profitability led to a decline in stock price. 2. There have been no other significant news recently. Market concerns about future profitability have led to a decline in stock price. **Top Stocks by Industry Trading Volume** AbbVie rose 3.40%. Based on recent news, 1. On July 15, analyst Justin Miller maintained a buy rating on AbbVie, stating that its proposed $10.9 billion acquisition of Apogee Therapeutics would strengthen its immunology business and help address future patent expiration issues. The analyst noted that AbbVie's current valuation does not reflect the potential of the Apogee pipeline. This news boosted market confidence and drove the stock price up. 2. On July 15, AbbVie's Skyrizi and Rinvoq grew by 31% and 23% respectively in the first quarter of 2026, exceeding market expectations. This demonstrated the company's strong performance in the immunology field, further driving the stock price up. 3. On July 16, despite high premium acquisition integration risks and pressure from Medicare price negotiations, AbbVie is still considered a quality investment target with high dividend yields. Investors remain optimistic about its long-term growth prospects, driving the stock price up. Strong performance in the immunology field and attractive dividend yields are drawing investors. Gilead Sciences rose 2.45%. Based on recent key news: 1. On July 16, Gilead Sciences announced that its BDR program in Brazil will adjust the ratio of underlying assets to BDRs and conduct a mandatory stock split. This move may enhance investor interest in the stock, driving the price up. Source: Public Technologies 2. On July 16, Gilead Sciences' experimental cancer drug anito-cel is awaiting a decision from the U.S. FDA. The market holds an optimistic view on the potential approval of this drug, which may drive the stock price up. Source: AppliedXL 3. On July 14, Gilead Sciences donated obeldesivir and remdesivir to support trials for the Ebola virus. This move demonstrates the company's active participation in global health, which may enhance its brand image. Source: Public Technologies The pharmaceutical industry is active in innovative drug development, attracting high market attention. Amgen rose 3.08%. Based on recent news, 1. On July 14, market analysts pointed out that although Amgen is currently rated as hold, top analysts believe there are five stocks that are more worthy of purchase, which may lead some investors to reassess their portfolios, driving the stock price up 2. On July 16, Citigroup analyst Geoff Meacham maintained a hold rating on Amgen and set a target price of $345. Meanwhile, Wells Fargo's Mohit Bansal also gave a hold rating, while Bank of America Securities reiterated a sell rating on Amgen. The combined impact of these ratings may attract market attention to Amgen's stock, leading to price fluctuations. 3. On July 14, investors focused on Amgen's growth prospects. Despite the drag from biosimilars, if input costs remain volatile and Most Favored Nation pricing tightens, Amgen's lower price-to-earnings ratio and operational oncology business become relatively more attractive, drawing more investor interest. There is a divergence in the market regarding Amgen's ratings and growth prospects. **Stocks Ranked Among the Top in Industry Market Capitalization** Forte Pharmaceuticals rose 1.86%. Based on recent news, 1. On July 14, Forte Pharmaceuticals announced that its new drug received FDA approval, boosting market confidence and driving the stock price up. 2. On July 15, Forte Pharmaceuticals released a strong quarterly financial report, showing revenue and profits exceeding expectations, further pushing the stock price higher. 3. On July 16, analysts raised the target price for Forte Pharmaceuticals, believing it has significant future growth potential, attracting more investors to buy in. The pharmaceutical industry has performed strongly recently, with noticeable capital inflows ### Related Stocks - [CBUS.US](https://longbridge.com/en/quote/CBUS.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) - [GILD.US](https://longbridge.com/en/quote/GILD.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) - [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md) ## Related News & Research - [Cibus (NASDAQ:CBUS) Releases Earnings Results, Misses Expectations By $0.16 EPS](https://longbridge.com/en/news/279491060.md) - [Cibus welcomes EU move to treat non-transgenic gene-edited crops as conventional breeding](https://longbridge.com/en/news/290051443.md) - [How Cibus Nordic Real Estate’s Q1 2026 Results and Nordic Acquisitions Will Impact Cibus Nordic Real Estate (OM:CIBUS) Investors](https://longbridge.com/en/news/285597409.md) - [Cibus to report Q2 2026 results after market close, host conference call](https://longbridge.com/en/news/294409540.md) - [A Look At Cibus Nordic Real Estate (OM:CIBUS) Valuation After New Perpetual Notes And Capital Structure Proposals](https://longbridge.com/en/news/278239664.md)